Loading
Life sciences · Journal article
BMC Gastroenterology · October 13, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Non-alcoholic fatty liver disease (NAFLD)/metabolic dysfunction-associated steatotic liver disease (MASLD), including cirrhosis, is an increasing global health concern, yet long-term trends, drivers, and subnational disparities remain inadequately characterized. We assessed the global burden and U.S. subnational variations using machine-learning-based attribution. Using Global Burden of Disease 2021 data, we analyzed global incidence, prevalence, disability-adjusted life years (DALYs), temporal trends, decomposition, inequalities, and Bayesian age-period-cohort projections through 2040. For complementary U.S. analyses, we used CDC WONDER data, extreme gradient boosting (XGBoost)–SHapley Additive exPlanations attribution, and autoregressive integrated moving average/Prophet forecasting. Globally, incident cases, prevalence, and DALYs approximately doubled from 1990 to 2021. Age-standardized incidence and prevalence increased, whereas DALY rates remained stable (estimated annual percentage change = 0.04), with population growth and aging identified as the main drivers. Absolute inequality, measured by the slope index of inequality (SII), widened from 20 to 36 per 100,000. High-burden regions included North Africa and the Middle East, Latin America, and Eastern Europe. In the U.S., the South and Midwest had the highest and fastest-growing mortality rates. XGBoost identified diabetes prevalence as the dominant state-level predictor, showing a nonlinear positive association above approximately 10–12%, whereas higher educational attainment showed an inverse association above approximately 90%. A sharp inflection in mortality occurred in 2020. Mortality is projected to increase through 2035, particularly in the Southwest and Appalachia. The absolute burden of NAFLD/MASLD, including cirrhosis, continues to rise despite stable age-standardized DALY rates. Global trends and U.S. machine-learning evidence indicate that prevention should shift toward systemic metabolic risk management, with liver fibrosis screening integrated into routine diabetes and obesity care.